IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Provided By GlobeNewswire
Last update: Nov 12, 2024
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer, today reported financial results for the third quarter ended September 30, 2024, and recent corporate highlights.
Read more at globenewswire.com0.1337
-0.01 (-9.78%)
Find more stocks in the Stock Screener
INAB Latest News and Analysis
7 days ago - ChartmillThese stocks are moving in today's after hours sessionLet's have a look at what is happening on the US markets after the closing bell on Monday. Below you can find the top gainers and losers in today's after hours session.
